Corning® Epic® System Enables Discovery of Biological Processes
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Corning Incorporated has announced research results using label-free Corning® Epic® technology to study new areas of cell biology, which may yield important insights for basic biological research and drug discovery applications.
According to research published recently in J Biol Chem, investigators from the University of Bonn have uncovered a new way by which receptors regulate themselves and limit the extent of their own cellular responses, thereby preventing overstimulation. This is a significant development in the current understanding of receptor biology and could help discover better therapeutic drugs.
According to Professor Evi Kostenis, Ph.D, chair, Molecular, Cellular and Pharmacobiology, Institute for Pharmaceutical Biology, University of Bonn, Germany, and senior author of the J Biol Chem study, “the novel technology is a breakthrough in both basic research and drug development. To date, it has been impossible to analyze activation of receptors and their various routes of communication with the cell interior in living cells and real time. The Epic biosensor has overcome this limitation: It captures receptor-mediated rearrangements of intracellular components and translates such rearrangements into specific optical signals. We are pleased to take advantage of this technology to both discover novel biological principles, but also to develop novel therapeutics designed to interfere with very specific cellular functions.”
“This is a great example of how label-free technology is being used to make new biological discoveries, and it underscores the future potential of the technology,” added Ron Verkleeren, business director, Corning Epic system.
According to research published recently in J Biol Chem, investigators from the University of Bonn have uncovered a new way by which receptors regulate themselves and limit the extent of their own cellular responses, thereby preventing overstimulation. This is a significant development in the current understanding of receptor biology and could help discover better therapeutic drugs.
According to Professor Evi Kostenis, Ph.D, chair, Molecular, Cellular and Pharmacobiology, Institute for Pharmaceutical Biology, University of Bonn, Germany, and senior author of the J Biol Chem study, “the novel technology is a breakthrough in both basic research and drug development. To date, it has been impossible to analyze activation of receptors and their various routes of communication with the cell interior in living cells and real time. The Epic biosensor has overcome this limitation: It captures receptor-mediated rearrangements of intracellular components and translates such rearrangements into specific optical signals. We are pleased to take advantage of this technology to both discover novel biological principles, but also to develop novel therapeutics designed to interfere with very specific cellular functions.”
“This is a great example of how label-free technology is being used to make new biological discoveries, and it underscores the future potential of the technology,” added Ron Verkleeren, business director, Corning Epic system.
